- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.3: 10 residues within 4Å:- Chain A: S.171, E.173, P.174, L.223, N.224, N.338, G.340, V.406, S.407
- Ligands: NAG.30
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:S.171, A:S.171
NAG-NAG-BMA-MAN.11: 9 residues within 4Å:- Chain E: P.174, V.216, L.223, N.224, N.338, G.340, V.406, S.407
- Ligands: NAG.44
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.17: 9 residues within 4Å:- Chain I: S.171, P.174, L.223, N.224, N.338, G.340, V.406, S.407
- Ligands: NAG.58
No protein-ligand interaction detected (PLIP)- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN.5: 21 residues within 4Å:- Chain A: T.98, Q.100, S.120, N.122
- Chain M: S.35, T.100, E.103, Y.105, Y.118, F.120, D.122
- Chain N: S.32, Y.33, Y.37, L.47, Y.50, G.51, S.53, S.54, Q.90, F.96
5 PLIP interactions:3 interactions with chain M, 2 interactions with chain N- Hydrogen bonds: M:E.103, M:E.103, M:Y.105, N:Y.50, N:G.51, N:S.54, N:S.53, N:S.53
- 6 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-FUC.6: 5 residues within 4Å:- Chain B: N.105, N.107, S.109, E.110
- Chain C: S.107
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:N.105, B:N.107
NAG-FUC.7: 4 residues within 4Å:- Chain B: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:S.102
- Hydrophobic interactions: B:Y.127
NAG-FUC.13: 7 residues within 4Å:- Chain F: N.105, R.106, N.107, S.109, E.110
- Chain G: S.107
- Ligands: NAG.48
2 PLIP interactions:1 interactions with chain F, 1 interactions with chain G- Hydrogen bonds: F:S.109, F:S.109, G:S.107, F:N.105
NAG-FUC.14: 5 residues within 4Å:- Chain F: N.100, S.102, W.103, Y.127, I.130
1 PLIP interactions:1 interactions with chain F- Hydrogen bonds: F:S.102
- Hydrophobic interactions: F:Y.127
NAG-FUC.20: 4 residues within 4Å:- Chain J: N.107, E.110
- Chain K: S.107
- Ligands: NAG.63
No protein-ligand interaction detected (PLIP)NAG-FUC.21: 3 residues within 4Å:- Chain J: N.100, S.102, Y.127
2 PLIP interactions:2 interactions with chain J- Hydrogen bonds: J:S.102, J:S.102
- Hydrophobic interactions: J:Y.127
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.22: 3 residues within 4Å:- Chain A: E.57, N.58
- Chain B: S.17
Ligand excluded by PLIPNAG.23: 4 residues within 4Å:- Chain A: N.196, T.198, S.236, H.313
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain A: N.107
Ligand excluded by PLIPNAG.25: 1 residues within 4Å:- Chain A: N.316
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain A: N.238, N.241
Ligand excluded by PLIPNAG.27: 4 residues within 4Å:- Chain A: Q.324, S.349, N.353
- Ligands: NAG-NAG.1
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain A: K.296, N.300, W.356
Ligand excluded by PLIPNAG.29: 5 residues within 4Å:- Chain A: Q.255, N.257, N.293, S.295, R.404
Ligand excluded by PLIPNAG.30: 4 residues within 4Å:- Chain A: N.224, P.253, N.408
- Ligands: NAG-NAG-BMA-MAN.3
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: N.263, I.284, V.402
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain A: R.154, N.159, T.160
- Chain E: R.270
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain A: N.103, G.114, K.117
Ligand excluded by PLIPNAG.34: 4 residues within 4Å:- Chain B: K.122, E.123, N.126, Y.127
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain B: D.113, N.114
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain E: E.57, N.58
- Chain F: S.17
Ligand excluded by PLIPNAG.37: 5 residues within 4Å:- Chain E: N.196, T.198, S.236, I.239, H.313
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain E: N.107
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain E: N.316
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain E: N.238, T.240, N.241
Ligand excluded by PLIPNAG.41: 4 residues within 4Å:- Chain E: Q.324, S.349, N.353
- Ligands: NAG-NAG.9
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain E: K.296, N.300, W.356
Ligand excluded by PLIPNAG.43: 5 residues within 4Å:- Chain E: Q.255, N.257, N.293, S.295, R.404
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain E: V.406, S.407, N.408
- Ligands: NAG-NAG-BMA-MAN.11
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain E: N.263, I.284, V.402
Ligand excluded by PLIPNAG.46: 5 residues within 4Å:- Chain E: V.144, R.154, N.159, T.160
- Chain I: R.270
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain E: N.103, G.114, K.117
Ligand excluded by PLIPNAG.48: 5 residues within 4Å:- Chain F: S.109, E.110, D.113, N.114
- Ligands: NAG-FUC.13
Ligand excluded by PLIPNAG.49: 3 residues within 4Å:- Chain F: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.50: 5 residues within 4Å:- Chain I: E.57, N.58
- Chain J: G.13, G.16, S.17
Ligand excluded by PLIPNAG.51: 4 residues within 4Å:- Chain I: N.196, T.198, S.236, H.313
Ligand excluded by PLIPNAG.52: 1 residues within 4Å:- Chain I: N.107
Ligand excluded by PLIPNAG.53: 1 residues within 4Å:- Chain I: N.316
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain I: N.238, T.240
Ligand excluded by PLIPNAG.55: 4 residues within 4Å:- Chain I: S.349, N.353
- Ligands: NAG-NAG.15, NAG-NAG.15
Ligand excluded by PLIPNAG.56: 2 residues within 4Å:- Chain I: N.300, W.356
Ligand excluded by PLIPNAG.57: 5 residues within 4Å:- Chain I: Q.255, N.257, N.293, S.295, R.404
Ligand excluded by PLIPNAG.58: 4 residues within 4Å:- Chain I: V.406, S.407, N.408
- Ligands: NAG-NAG-BMA-MAN.17
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain I: N.263, I.284, V.402
Ligand excluded by PLIPNAG.60: 4 residues within 4Å:- Chain A: R.270
- Chain I: R.154, N.159, T.160
Ligand excluded by PLIPNAG.61: 3 residues within 4Å:- Chain I: N.103, R.113, G.114
Ligand excluded by PLIPNAG.62: 3 residues within 4Å:- Chain J: K.122, E.123, N.126
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain J: S.109, N.114
- Ligands: NAG-FUC.20
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Melzi, E. et al., Priming HIV Envelope V2 Apex-directed broadly neutralizing antibody responses with protein or mRNA immunogens. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT2 gp120: AEI
HIV Envelope ApexGT2 gp41: BFJ
RM20A3 Fab Heavy Chain: CGK
RM20A3 Fab Light Chain: DHL
GT2-d42.16 Fab Heavy Chain: M
GT2-d42.16 Fab Light Chain: N - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
EB
BF
DJ
FC
JG
MK
OD
KH
NL
PM
HN
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Melzi, E. et al., Priming HIV Envelope V2 Apex-directed broadly neutralizing antibody responses with protein or mRNA immunogens. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT2 gp120: AEI
HIV Envelope ApexGT2 gp41: BFJ
RM20A3 Fab Heavy Chain: CGK
RM20A3 Fab Light Chain: DHL
GT2-d42.16 Fab Heavy Chain: M
GT2-d42.16 Fab Light Chain: N - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
EB
BF
DJ
FC
JG
MK
OD
KH
NL
PM
HN
L